- $49.40m
- $56.18m
- $26.49m
- 80
- 54
- 89
- 88
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.8 | ||
| Price to Tang. Book | 1.8 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.86 | ||
| EV to EBITDA | 53.66 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.03% | ||
| Return on Equity | -8.21% | ||
| Operating Margin | -6.19% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 15.34 | 19.24 | 18.57 | 17.47 | 26.49 | n/a | n/a | 14.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Directors
- David Tomsche CHM (64)
- Michael Brigham PRE (60)
- Joseph Crabb CSO (66)
- Bobbi Brockmann VPR (45)
- Elizabeth Williams VPR (65)
- Gloria Basse IND (61)
- David Cunningham IND (55)
- Steven Rosgen IND (55)
- Jonathan Rothschild IND (67)
- Paul Wainman IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 9th, 1987
- Public Since
- May 1st, 1987
- No. of Shareholders
- 572
- No. of Employees
- 69
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 8,994,425
- Address
- 56 Evergreen Drive, PORTLAND, 04103
- Web
- https://immucell.com/
- Phone
- +1 2078782770
- Auditors
- Wipfli LLP
Upcoming Events for ICCC
Q1 2025 ImmuCell Corp Earnings Call
ImmuCell Corp Annual Shareholders Meeting
ImmuCell Corp Annual Shareholders Meeting
Q2 2025 ImmuCell Corp Earnings Release
Similar to ICCC
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the ImmuCell share price?
As of Today at 21:15 UTC, shares in ImmuCell are trading at $5.50. This share price information is delayed by 15 minutes.
How has the ImmuCell share price performed this year?
Shares in ImmuCell last closed at $5.50 and the price had moved by +7.84% over the past 365 days. In terms of relative price strength the ImmuCell share price has underperformed the S&P500 Index by -0.46% over the past year.
What are the analyst and broker recommendations for ImmuCell?
The overall consensus recommendation for ImmuCell is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the ImmuCell dividend yield?
ImmuCell does not currently pay a dividend.
Does ImmuCell pay a dividend?
ImmuCell does not currently pay a dividend.
When does ImmuCell next pay dividends?
ImmuCell does not currently pay a dividend.
How do I buy ImmuCell shares?
To buy shares in ImmuCell you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ImmuCell?
As of the previous close price of $5.50, shares in ImmuCell had a market capitalisation of $49.40m.
Where are ImmuCell shares listed?
Here are the trading details for ImmuCell:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ICCC
What kind of share is ImmuCell?
Based on an overall assessment of its quality, value and momentum ImmuCell is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ImmuCell share price forecast for 2025?
The analyst consensus target price for shares in ImmuCell is $14.00. That is 154.55% above the last closing price of $5.50.
Analysts covering ImmuCell currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the ImmuCell share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ImmuCell. Over the past six months, its share price has outperformed the S&P500 Index by +59.96%.
As of the last closing price of $5.50, shares in ImmuCell were trading +24.71% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ImmuCell PE Ratio?
The ImmuCell PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ImmuCell?
ImmuCell's management team is headed by:
- David Tomsche - CHM
- Michael Brigham - PRE
- Joseph Crabb - CSO
- Bobbi Brockmann - VPR
- Elizabeth Williams - VPR
- Gloria Basse - IND
- David Cunningham - IND
- Steven Rosgen - IND
- Jonathan Rothschild - IND
- Paul Wainman - IND